



## ASX ANNOUNCEMENT

**Simavita releases ASX Appendix 4C for the quarter ended December 31, 2019**

**For Immediate Release:**

**January 29, 2020**

**Sydney, Australia** – Simavita Limited (ASX: SVA) today reported its December 31, 2019 quarter end results.

- Simavita ended the quarter for the period to December 31, 2019 with cash reserves of AUD\$806k.
- Simavita continues to tightly manage ongoing operating costs with total cash outflows for the quarter of \$1.15m. This is an increase of 5% on previous quarter. Quarter on quarter there was a \$41k increase in corporate costs which included legal fees associated with drafting limited licensing agreements for in market trials, audit fees and tax advice.
- During the quarter under review, the Company received \$1m from Convertible Notes. These Notes were approved by shareholders at a Special General Meeting dated June 24, 2019.
- Forecast cash outflows for the quarter to March 31, 2020 are anticipated to be \$1.24m including additional commercialisation costs.
- The Company expects to have negative operating cash flows whilst it builds a sustainable revenue pipeline. During this period the Company may continue to rely upon the support of its major shareholders. If required, the Company will raise additional cash to fund operations and to meet its business objectives.
- The Company's focus for the following quarter includes:
  - Progress key commercialisation activities in major markets
  - Focus on sales and marketing
  - Continuous software development for key Apps
  - Deliver key product lines in conjunction with manufacturing partners
  - Continue strategic field testing with partner organisations
  - Progress activities associated with a reorganisation of the Company
- The Company is in continuing dialogue with an increasing number of major organisations with specific interest in our platform technology. These discussions are often complex, relate to major installations and may be of varying duration. The Company is committed to informing our shareholders and market should these discussions translate into signed licensing agreements that are material to the Company and its operations.
- Preliminary 'in-market' trials have been conducted in Australia and further trials of the technology will commence internationally during Q1 2020.
- Simavita's business model is to license our technology and to deliver service to our customers. This model allows the customer to implement the technology rapidly and without capital expenditure or impact upon manufacturing efficiency.

- The Company's current and budgeted operating costs are relatively low and stable. Accordingly, and in line with software industry standards, the Company anticipates strong future profit margins.
- The Company confirms that it continues to be in compliance with Listing Rules 3.1 and 12.2.
- The above statements have been authorised and approved in accordance with the Company's published continuous disclosure policy.

For further information, please view our website ([www.simavita.com](http://www.simavita.com)) or contact:

Ms Peta Jurd  
Chief Commercial Officer

E: [pjurd@simavita.com](mailto:pjurd@simavita.com)  
T: +61 421 466 653  
W: Investor Centre: [Click here](#)

*This ASX announcement was approved and authorised for release by the Board of Simavita Limited.*

## About Simavita

Simavita (ASX: SVA) is a MedTech Company focused on the development of smart, wearable and disposable platform technologies for the health care market.

Our key platform Smartz™ is a highly disruptive technology focused on transforming a traditional "dumb" diaper into a smart device to help parents and carers of both infants and adults.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. [www.simavita.com](http://www.simavita.com)

## Forward-Looking Information

*This document may contain "forward-looking information" within the meaning of Canadian securities laws ("forward-looking information"). This forward-looking information is given as of the date of this document.*

*Forward-looking information relates to future events or future performance and reflects Simavita management's expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.*

*In certain cases, forward-looking information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or information that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita's interim and annual financial statements and management's discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.*

Simavita Limited  
Level 2, 54 Miller Street, North Sydney NSW 2060  
Telephone: + 61 2 8405 6300

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity  
**SIMAVITA LIMITED**

ARBN  
165 831 309

Quarter ended:  
31 December 2019

#### Consolidated statement of cash flows

	Current quarter \$A'000	Year to date (six months) \$A'000
<b>1 Cash flows from operating activities</b>		
1.1 Receipts from customers	13	29
1.2 Payments for		
(a) research and development	(113)	(194)
(b) product manufacturing and operating costs	(23)	(42)
(c) advertising and marketing	(48)	(135)
(d) leased assets	-	-
(e) staff costs	(559)	(1,101)
(f) administration and corporate costs	(438)	(835)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	684	684
1.8 Other: GST refund	29	59
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(455)</b>	<b>(1,535)</b>
<b>2 Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	(8)
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>-</b>	<b>(8)</b>
<b>3 Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	1,000	1,750
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	212	212
3.6 Repayment of borrowings	(304)	(304)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.1 Net cash from / (used in) financing activities</b>	<b>908</b>	<b>1,658</b>

#### 4 Net increase / (decrease) in cash and cash equivalents for the period

	Current quarter \$A'000	Year to date (six months) \$A'000
4.1 Cash and cash equivalents at beginning of quarter/year to date	352	689
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(455)	(1,535)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	(8)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	908	1,658
4.5 Effect of movement in exchange rates on cash held	1	2
<b>4.6 Cash and cash equivalents at end of quarter</b>	<b>806</b>	<b>806</b>

#### 5 Reconciliation of cash and cash equivalents

at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts

	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	806	352
5.2 Call deposits		
5.3 Bank overdrafts		
5.4 Other (provide details)	-	-
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>806</b>	<b>352</b>

#### 6 Payments to directors of the entity and their associates

	Current quarter \$A'000
6.1 Aggregate amount of payments to these parties included in item 1.2	117
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	Directors' Fees plus superannuation

#### 7 Payments to related entities of the entity and their associates

	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	None

#### 8 Financing facilities available

Add notes as necessary for an understanding of the position

	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	4,540	4,540
8.2 Credit standby arrangements	None	None
8.3 Other: 2020 R&D tax incentive-Receiveable Finance Facility	636	212

- 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

1) Convertible notes issued in April 2018, totalling \$1.4m which are either convertible or redeemable on 31 March 2020 Coupon rate of 10% per annum, with interest payable on Maturity Date.

2) Convertible notes issued in April 2019, totalling \$3.14m which are either convertible or redeemable on 30 April 2022 Coupon rate of 10% per annum, with interest payable on Maturity Date.

3) Finance provider: Antra Group Pty Ltd. Loan secured by the Group. Establishment fee at 5% p.a. and capitalised interest at 16% p.a. Facility to be repaid by the Group once the 2020 R&D tax incentive is received from the ATO.

<b>9 Estimated cash outflows for next quarter</b>	<b>\$A'000</b>
9.1 Research and development	(140)
9.2 Product manufacturing and operating costs	(20)
9.3 Advertising and marketing	(80)
9.4 Leased assets	-
9.5 Staff costs	(560)
9.6 Administration and corporate costs	(440)
9.7 Other (provide details if material)	-
<b>9.8 Total estimated cash outflows</b>	<b>(1,240)</b>

<b>10 Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	<b>Acquisitions</b>	<b>Disposals</b>
10.1 Name of entity	Not applicable	Not applicable
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

#### Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.



Sign here: .....  
Company secretary

Date: 29 January, 2020

Print name: Peta C. Jurd

#### Notes

- The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.